Novo stock drops 15% as obesity drug falls short in key trial

Core Viewpoint - Novo Nordisk's stock dropped 15% after its obesity drug CagriSema underperformed in a key trial compared to Eli Lilly's tirzepatide, raising concerns about its market position and future potential [1]. Group 1: Trial Results - CagriSema achieved an average weight loss of 20.2% after 84 weeks, while Lilly's tirzepatide resulted in 23.6% weight loss, indicating a significant performance gap [1]. - The trial missed its primary endpoint of demonstrating non-inferiority in weight loss compared to tirzepatide, marking a setback for Novo in the competitive obesity drug market [1]. Group 2: Market Impact - Following the trial results, Novo shares fell by as much as 15.4% in Copenhagen trading, while Lilly shares rose by 4.2% in premarket US trading, reflecting market disappointment in CagriSema's effectiveness [1]. - The results could limit CagriSema's commercial potential as Novo faces pressure to regain market share lost to Lilly's products [1]. Group 3: Strategic Importance - CagriSema is a central element of Novo's long-term obesity strategy, especially as patents for its existing drugs, Wegovy and Ozempic, approach expiry [1]. - The injection combines semaglutide with cagrilintide to enhance appetite suppression and improve weight-loss outcomes, but the trial results have raised doubts about its competitive edge [1]. Group 4: Management and Company Performance - The trial setback occurs amid significant internal changes at Novo, including a new CEO and board-level departures due to competitive performance concerns [1]. - Novo's market value has decreased to approximately $189 billion, down from a peak of over $600 billion in 2024, with shares falling more than 58% over the past year [1]. - The new CEO has announced job cuts and is actively seeking future obesity deals, indicating a strategic pivot in response to recent challenges [1].